相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting
Melissa L. Geddie et al.
MABS (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Hana Starobova et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2017)
The antibody-drug conjugate target landscape across a broad range of tumour types
K. L. Moek et al.
ANNALS OF ONCOLOGY (2017)
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Helen Lee et al.
CLINICAL CANCER RESEARCH (2017)
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Ramesh K. Ramanathan et al.
CLINICAL CANCER RESEARCH (2017)
EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Philip D. Dunne et al.
CLINICAL CANCER RESEARCH (2016)
A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets
John J. Rhoden et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer
Ketan Patel et al.
MOLECULAR PHARMACEUTICS (2016)
Antibody Drug Conjugates for Cancer Therapy
Paul Polakis
PHARMACOLOGICAL REVIEWS (2016)
Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
Hiroshi Maeda
ADVANCED DRUG DELIVERY REVIEWS (2015)
Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance
Irina Kareva et al.
CANCER LETTERS (2015)
Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells
Bainan Wu et al.
CHEMISTRY & BIOLOGY (2015)
Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer
Hannah A. Blair et al.
DRUGS (2015)
The interaction of 4-thiazolidinone derivatives containing indolin-2-one moiety with P-glycoprotein studied using K562 cell lines
Feng Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Receptor-mediated membrane adhesion of lipid-polymer hybrid (LPH) nanoparticles studied by dissipative particle dynamics simulations
Zhenlong Li et al.
NANOSCALE (2015)
Clinical overview of metronomic chemotherapy in breast cancer
Elisabetta Munzone et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
Ashish V. Kalra et al.
CANCER RESEARCH (2014)
Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System
Elisa Barile et al.
CHEMMEDCHEM (2014)
EphA2 Targeting Pegylated Nanocarrier Drug Delivery System for Treatment of Lung Cancer
Apurva R. Patel et al.
PHARMACEUTICAL RESEARCH (2014)
Presentation and management of docetaxel-related adverse effects in patients with breast cancer
Maria Y. Ho et al.
CANCER MANAGEMENT AND RESEARCH (2014)
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Christina M. Annunziata et al.
INVESTIGATIONAL NEW DRUGS (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis
Ta-Chen Huang et al.
CANCER TREATMENT REVIEWS (2012)
Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis
Ruth Holm et al.
International Journal of Medical Sciences (2012)
Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma
Masashi Ishikawa et al.
LUNG CANCER (2012)
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
Jeffrey Hrkach et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer
Yesim Goekmen-Polar et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells
Nai-Ying Yang et al.
CELLULAR SIGNALLING (2011)
Emerging strategies for EphA2 receptor targeting for cancer therapeutics
Manish Tandon et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck
Yong Liu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Eph/Ephrin Profiling in Human Breast Cancer Reveals Significant Associations between Expression Level and Clinical Outcome
Dana M. Brantley-Sieders et al.
PLOS ONE (2011)
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer
William M. Merritt et al.
CANCER BIOLOGY & THERAPY (2010)
Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis
Davide Mauri et al.
CANCER TREATMENT REVIEWS (2010)
Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles
Igor V. Zhigaltsev et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Internalizing Cancer Antibodies from Phage Libraries Selected on Tumor Cells and Yeast-Displayed Tumor Antigens
Yu Zhou et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer
Jennifer M. Brannan et al.
CLINICAL CANCER RESEARCH (2009)
Over-Expression of EphA2 and EphrinA-1 in Human Gastric Adenocarcinoma and Its Prognostic Value for Postoperative Patients
Wei-Jie Yuan et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
William J. Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties
Daniel Zucker et al.
JOURNAL OF CONTROLLED RELEASE (2009)
Improved Pharmacokinetics and Efficacy of a Highly Stable Nanoliposomal Vinorelbine
Daryl C. Drummond et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo
Dowdy Jackson et al.
CANCER RESEARCH (2008)
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling
Dana M. Brantley-Sieders et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Pharmacokinetics and In Vivo Drug Release Rates in Liposomal Nanocarrier Development
Daryl C. Drummond et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor-expressing tumor cells
Jill Wykosky et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice
Weibo Cai et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Impact of single-chain fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells
Yu Zhou et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Effect of vascular normalization, by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: Insights from a mathematical model
Rakesh K. Jain et al.
CANCER RESEARCH (2007)
Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status
Shiyama V. Mudali et al.
CLINICAL & EXPERIMENTAL METASTASIS (2006)
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
DC Drummond et al.
CANCER RESEARCH (2006)
Expression of EphA2 and ephrin A-1 in carcinoma of the urinary bladder
S Abraham et al.
CLINICAL CANCER RESEARCH (2006)
Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate
Stewart D. Chipman et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2006)
Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-Lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis
DF Nellis et al.
BIOTECHNOLOGY PROGRESS (2005)
Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification
DF Nellis et al.
BIOTECHNOLOGY PROGRESS (2005)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
A Sparreboom et al.
CLINICAL CANCER RESEARCH (2005)
Microtubules as a target for anticancer drugs
MA Jordan et al.
NATURE REVIEWS CANCER (2004)
EphA2 expression is associated with aggressive features in ovarian carcinoma
PH Thaker et al.
CLINICAL CANCER RESEARCH (2004)
Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery
A Safavy et al.
BIOCONJUGATE CHEMISTRY (2003)
EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma
T Miyazaki et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia
GY Zeng et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis
UB Nielsen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2002)
分享论文
